1. Home
  2. SPRO vs MGYR Comparison

SPRO vs MGYR Comparison

Compare SPRO & MGYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • MGYR
  • Stock Information
  • Founded
  • SPRO 2013
  • MGYR 1922
  • Country
  • SPRO United States
  • MGYR United States
  • Employees
  • SPRO N/A
  • MGYR N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • MGYR Savings Institutions
  • Sector
  • SPRO Health Care
  • MGYR Finance
  • Exchange
  • SPRO Nasdaq
  • MGYR Nasdaq
  • Market Cap
  • SPRO 107.5M
  • MGYR 98.9M
  • IPO Year
  • SPRO 2017
  • MGYR 2006
  • Fundamental
  • Price
  • SPRO $1.87
  • MGYR $17.48
  • Analyst Decision
  • SPRO Buy
  • MGYR
  • Analyst Count
  • SPRO 4
  • MGYR 0
  • Target Price
  • SPRO $5.00
  • MGYR N/A
  • AVG Volume (30 Days)
  • SPRO 798.2K
  • MGYR 2.4K
  • Earning Date
  • SPRO 08-12-2025
  • MGYR 07-24-2025
  • Dividend Yield
  • SPRO N/A
  • MGYR 2.06%
  • EPS Growth
  • SPRO N/A
  • MGYR 35.01
  • EPS
  • SPRO N/A
  • MGYR 1.57
  • Revenue
  • SPRO $48,576,000.00
  • MGYR $35,533,000.00
  • Revenue This Year
  • SPRO N/A
  • MGYR N/A
  • Revenue Next Year
  • SPRO N/A
  • MGYR N/A
  • P/E Ratio
  • SPRO N/A
  • MGYR $11.16
  • Revenue Growth
  • SPRO N/A
  • MGYR 18.29
  • 52 Week Low
  • SPRO $0.51
  • MGYR $12.10
  • 52 Week High
  • SPRO $3.22
  • MGYR $19.04
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 35.23
  • MGYR 59.19
  • Support Level
  • SPRO $1.80
  • MGYR $17.08
  • Resistance Level
  • SPRO $2.38
  • MGYR $17.51
  • Average True Range (ATR)
  • SPRO 0.12
  • MGYR 0.21
  • MACD
  • SPRO -0.02
  • MGYR -0.01
  • Stochastic Oscillator
  • SPRO 12.07
  • MGYR 64.38

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About MGYR Magyar Bancorp Inc.

Magyar Bancorp Inc is a mid-tier stock holding company. The Company offers a full array of commercial and retail financial services, including the taking of time, savings and demand deposits; the making of commercial, consumer and home equity loans; and the provision of other financial services. The business consists of getting retail deposits from the general public in the areas surrounding the main office in New Brunswick, New Jersey and branch offices located in Middlesex and Somerset Counties, New Jersey, and investing those deposits, together with funds generated from operations and wholesale funding, in residential mortgage loans, home equity loans, home equity lines of credit, commercial real estate loans, commercial business loans, Small Business Administration loans.

Share on Social Networks: